Correlation of expression of epithelial cell adhesion molecule and lymph node metastasis of breast cancer

Abstract

Abstract:ObjectiveTo investigate the expression and significance of epithelial cell adhesion molecule (EpCAM) in breast cancer. MethodsTwentythree cases of breast cancer tissue samples and paired lymph node metastases confirmed pathologically were collected. Isobaric tags for relative and absolute quantitation (iTRAQ) proteomics technology was used to screen and identify the differentially expressed proteins between primary tumor and lymph node metastasis of breast cancer. The expression of EpCAM was detected by Western blotting in 4 cases of primary breast cancer tissues and paired lymph node metastases. And the expressions of EpCAM in 252 cases of breast lesions were detected by immunohistochemical method. ResultsQuantitative proteomic examination results showed that differentially expressed proteins existed in breast cancer primary tumor and lymph node metastasis, and the expression of EpCAM in metastatic lesions was higher than that in primary tumor. Western blotting results showed that the expression of EpCAM in metastatic lesions (1.46±0.22) was higher than that in primary tumor (1.16±0.09), which was consistent with the results of proteomic. The immunohistochemical results showed that the positive expression rate of EpCAM in lymph node metastasis tissues (93.16%, 109/117) was significantly higher than that in primary breast cancer without metastasis (72.73%, 64/88), and the difference was statistically significant (χ2=15.921, P=0.000). The positive expression rate of EpCAM in primary breast cancer with lymphatic metastasis (72.65%, 85/117) was lower than that in paired lymph node metastases (P=0.001). ConclusionEpCAM is differentially expressed in primary tumor and lymph node metastasis of breast cancer, which may be related to the lymphatic metastasis of breast cancer.

Key words:Cell adhesion molecule,Breast neoplasms,Proteomics,Immunohistochenmistry

Zhang Weiwei, Zhong Jingmin, Li Jing, Huang Sanqian, Liu Zhihong, Zeng Liang. Correlation of expression of epithelial cell adhesion molecule and lymph node metastasis of breast cancer[J]. Journal of International Oncology, 2017, 44(3): 177-181.

References

［1］ DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013［J］. CA Cancer J Clin, 2014, 64(1): 52-62. DOI: 10.3322/caac.21203. ［2］ Youlden DR, Cramb SM, Yip CH, et al. Incidence and mortality of female breast cancer in the AsiaPacific region［J］. Cancer Biol Med, 2014, 11(2): 101-115. DOI: 10.7497/j.issn.20953941.2014.02.005. ［3］ Sharifian A, Pourhoseingholi MA, Emadedin M, et al. Burden of breast cancer in Iranian women is increasing［J］. Asian Pac J Cancer Prev, 2015, 16(12): 50495052. ［4］ Fry SA, Sinclair J, Timms JF, et al. A targeted glycoproteomic approach identifies cadherin5 as a novel biomarker of metastatic breast cancer［J］. Cancer Lett, 2013, 328(2): 335-344. DOI: 10.1016/j.canlet.2012.10.011. ［5］ Onishi T, Hayashi N, Theriault RL, et al. Future directions of bonetargeted therapy for metastatic breast cancer［J］. Nat Rev Clin Oncol, 2010, 7(11): 641-651. DOI: 10.1038/nrclinonc.2010.134. ［6］ Zeng Q, Zhang P, Wu Z, et al. Quantitative proteomics reveals ERα involvement in CD146induced epithelialmesenchymal transition in breast cancer cells［J］. J Proteomics, 2014, 103: 153-169. DOI: 10.1016/j.jprot.2014.03.033. ［7］ Wilhelm M, Schlegl J, Hahne H. et al. Massspectrometrybased draft of the human proteome［J］. Nature, 2014, 509(7502): 582-587. DOI: 10.1038/nature13319. ［8］ Seviour EG, Sehgal V, Lu Y, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phosphoRb signature in breast and ovarian cancer［J］. Oncogene, 2016, 35(6): 801. DOI: 10.1038/onc.2015.177. ［9］ Nagano K. Challenge to the development of molecular targeted therapy against a novel target candidate identified by antibody proteomics technology［J］. Yakugaku Zasshi, 2016, 136(2): 145-149. DOI: 10.1248/yakushi.15002261. ［10］ Bonaldi T, Noberini R. Recent advances in mass spectrometry analysis of histone posttranslational modifications: potential clinical impact of the PATHMS approach［J］. Expert Rev Proteomics, 2016, 13(3): 245-250. DOI: 10.1586/14789450.2016.1147960. ［11］ Gastl G, Spizzo G, Obrist P, et al. EpCAM overexpression in breast cancer as a predictor of survival［J］. Lancet, 2000, 356(9246): 1981-1982. DOI: 10.1016/S01406736(00)033122. ［12］ Ni J，Cozzi PJ，Duan W, et al. Role of the EpCAM (CD326) in prostate cancer metastasis and progression［J］. Cancer Metastasis Rev, 2012, 31(34): 779-791. DOI: 10.1007/s1055501293891. ［13］ Zhou N, Wang H, Liu H. MTA1upregulated EpCAM is associated with metastatic behaviors and poor prognosis in lung cancer［J］. J Exp Clin Cancer Res, 2015, 34: 157. DOI: 10.1186/s1304601502631. ［14］ Lin Z, Lu X, Li W, et al. Association of cancer stem cell markers with aggressive tumor features in papillary thyroid carcinoma［J］. Cancer Control, 2015, 22(4): 508-514. ［15］ Sung JJ, Noh SJ, Bae JS, et al. Immunohistochemical expression and clinical significance of suggested stem cell markers in hepatocellular carcinoma［J］. J Pathol Transl Med, 2016, 50(1): 52-57. DOI: 10.4132/jptm.2015.10.09. ［16］ Gao J, Liu X, Yang F, et al. By inhibiting Ras/Raf/ERK and MMP9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis［J］. Oncotarget, 2015, 6(29): 27187-27198. DOI: 10.18632/oncotarget.4551. ［17］ Kubisch I, de Albuquerque A, Schuppan D, et al. Prognostic role of a multimarker analysis of circulating tumor cells in advanced gastric and gastroesophageal adenocarcinomas［J］. Oncology, 2015, 89(5): 294-303. DOI: 10.1159/000437373. ［18］ Mu Y, Sa N, Yu L, et al. Epithelial cell adhesion molecule is overexpressed in hypopharyngeal carcinoma and suppresses the metastasis and proliferation of the disease when downregulated［J］. Oncol Lett, 2014, 8(1): 175-182. DOI: 10.3892/ol.2014.2140. ［19］ Matsuda T, Takeuchi H, Matsuda S, et al. EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma［J］. Ann Surg Oncol, 2014, 21 Suppl 3: S356364. DOI: 10.1245/s1043401435798. ［20］ Romeu C, Farré X, Cardesa A, et al. Expression of EpCAM, but not of E48, associates with nodal involvement in advanced squamous cell carcinomas of the larynx［J］. Histopathology, 2013, 62(6): 954-961. DOI: 10.1111/his.12108. ［21］ Takes RP, Baatenburg de Jong RJ, Wijffels K, et al. Expression of genetic markers in lymph node metastases compared with their primary tumours in head and neck cancer［J］. J Pathol, 2001, 194(3): 298-302. DOI: 10.1002/10969896(200107)194:3<298::AIDPATH900>3.0.CO;2Q. ［22］ PituchNoworolska A, Drabik G, Szatanek R, et al. Immunophenotype of isolated tumour cells in the blood, bone marrow and lymph nodes of patients with gastric cancer［J］. Pol J Pathol, 2007, 58(2): 93-97.

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Li Lixi, Zhang Di, Luo Yang, Ma Fei.Clinical application of PARP inhibitors in breast cancer[J]. Journal of International Oncology, 2023, 50(2): 91-96.
[15]	Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng.Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors[J]. Journal of International Oncology, 2023, 50(11): 650-654.